Results from this study have shown that anti-thymocyte globulin ATG given at low dose (2.5 mg/kg) combined with the administration of 6 mg subcutaneously every 2 weeks for six doses of pegylated granulocyte colony-stimulating factor GCSF in individuals with T1D (duration 4–24 months) is able to preserve C-peptide (76, 77), contrary to higher doses of ATG (6.5 mg/kg) in monotherapy (78, 79). This evidence concerns the gene CSF3 and type 1 diabetes mellitus.